25 nov: Matas mærker stigende interesse blandt kunderne på Black Friday -..
25 nov: Shipping: Baltic Dry-indekset falder 1,7 pct. til 1181 point
25-11-2016 14:07:32

Zealand increases its share capital as a consequence of exercise of employee warrants

Relateret indhold
23 mar - 
Zealand Pharma: CFO sælger aktier for små 210.000 kr.
20 mar - 
Tirsdagens aktier: Mærsk trykket af direktørskifte i nø..
20 mar - 
Zealand Pharma når positive resultater med diabetes 1-m..
Relateret debat
18:44 - 
.. pipeline ..
18:41 - 
Som tidligere nævnt: "Hvilket andet dansk biotekselskab..
18:24 - 
Sanofi har det svært, men har de andre produkter til at..

Company announcement - No. 47 / 2016

 

 

Zealand increases its share capital as a consequence of exercise of employee warrants

Copenhagen, 25 November 2016 - Zealand Pharma ("Zealand") has increased its share capital with nominal DKK 57,913 divided into 57,913 new shares with a nominal value of DKK 1 each. The increase is a consequence of the exercise of warrants granted under three of Zealand's employee warrant programs.

Employee warrant programs are part of Zealand's incentive scheme, and each warrant gives the owner the right to subscribe for one new Zealand share at a pre-specified price, the exercise price, in specific pre-defined time periods before expiration. For further description of Zealand's warrant programs, see the company's Articles of Association, which are available on the homepage: www.zealandpharma.com.

The exercise price is DKK 77 per share for 35,851 of the new shares, DKK 50.27 per share for 17,062 of the new shares and DKK 87.45 per share for 5,000 of the new shares. The total proceeds to Zealand from the capital increase amounts to DKK 4,055,483.74.

The new shares give rights to dividend and other rights from the time of the warrant holder's exercise notice. Each new share carries one vote at Zealand's general meetings. Zealand only has one class of shares.

The new shares will be listed on Nasdaq Copenhagen after registration of the capital increase with the Danish Business Authority. Following registration of the new shares, the share capital of Zealand will be nominal DKK 26,128,366 divided into 26,128,366 shares with a nominal value of DKK 1 each.

The amendment of Zealand's Articles of Association entailed by the share capital increase has today been registered with the Danish Business Authority.

*****

For further information, please contact:

Mats Blom,

Senior Vice President, Chief Financial Officer

Tel: +45 31 53 79 73, email:mabl@zealandpharma.com

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a portfolio of medicines and product candidates under licence collaborations with Sanofi, Boehringer Ingelheim and Helsinn, and a pipeline of proprietary product candidates which primarily target specialty diseases with significant unmet needs.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed as Lyxumia® outside the United States and approved as Adlyxin(TM) in the United States. Lixisenatide has been developed in a fixed-ratio combination with basal insulin glargine (Lantus®) and is approved as Soliqua(TM) in the United States, and in Europe a CHMP positive opinion recommendation was given on 11 November. Suliqua(TM) is the brand name in Europe.

Zealand's proprietary pipeline includes: Dasiglucagon* (ZP4207) (single-dose rescue treatment) for acute, severe hypoglycaemia (Phase II); Glepaglutide* (ZP1848) for short bowel syndrome (Phase II); Dasiglucagon* (ZP4207) (multiple-dose version) intended for use in a dual-hormone artificial pancreas system for better hypoglycaemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about the company's business and activities, please visit www.zealandpharma.com or follow Zealand on Twitter @ZealandPharma.

* Dasiglucagon and Glepaglutide are proposed International Nonproprietary Names (pINN).

47-16_1125 Warrant exercise and capital increase


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Zealand Pharma via Globenewswire

Vedhæftet fil: 771857.pdf

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
14:22
ZEAL
Zealand Pharma success på Soliqua/Suliqua er fuldstændigt afhængigt af Sanofi’s success med diabetes..
9
21 apr
ZEAL
Der bliver nok 2018 som kommer til at afgøre Soliqua/Suliqua's skæbne i mine øjne. I 2017 var salget..
5
18 apr
ZEAL
Sjovt som du, Nada, ikke kan undvære at kommentere mine indlæg, nu hvor jeg lader dig fortælle om   ..
3
18 apr
ZEAL
Ja du er fuld af fup og fiduser 
3
18 apr
ZEAL
Solgt til Bioporto for en femmer 
3
18 apr
ZEAL
afnotering og tvangsindløsning.
3
22 apr
ZEAL
Ja du har jo opdaget triggertallet 3.800 uge 15 år 2, og det har markedet også kan vi aflæse.   Vict..
2
22 apr
ZEAL
ZP 2018 financial guidance   Revenue   Royalty revenue expected to significantly increase due to inc..
2
20 apr
ZEAL
Et mere relevant spørgmål er: hvorfor købe et massivt underskudsgivende selskab i forventning om ove..
2
19 apr
ZEAL
Kan se at Kirsten Drejer blev valgt ind i bestyrelsen. Hun er tidligere stifter og CEO for Symphogen..
2

Tivoli/CEO: Ny sæson og Tivoli Hjørnet øger omsætningen

23-04-2018 13:39:42
Den nye sæson hos forlystelsesparken Tivoli, Vinter I Tivoli, har sammen med åbningen af Tivoli Hjørnet bidraget til, at omsætningen er steget i første kvartal 2018.Det vurderer Lars Liebst, der er administrerende direktør i Tivoli. - Vi har haft åbent til Vinter i Tivoli og åbnet vores hjørne, og det har været gode ting. Det kan man se på omsætningen, siger Lars Liebst til Ritzau Finans.Nettoomsæ..

Vestas-konkurrent: Møllepriser er faldet 13 pct. på årsbasis

23-04-2018 07:00:55
Den amerikanske Vestas-konkurrent GE Renewable Energy melder om fortsat prispres, hvilket selskabet forsøger at kompensere for gennem omkostningsreduktioner. I første kvartal faldt priserne på nye mølleenheder til ordrebogen med 13 pct. i forhold til samme periode sidste år. Det sagde finansdirektøren for General Electric, som GE Renewable Energy er en del af, Jamie Miller, fredag på en telekonfer..

Bavarian: Udenlandske kapitalfonde øger væddemålet på kursfald

20-04-2018 16:36:15
En række kapitalfonde har onsdag og torsdag øget sine shortpositioner i biotekselskabet Bavarian Nordic. Det viser en række indberetninger til Finanstilsynet. Torsdag har Capital Partners øget sin shortposition til 0,62 pct. af aktierne fra 0,54 pct. Ligeledes har AHL Partners øget sin shortposition til 1,31 pct. af Bavarian-aktierne. Tidligere havde kapitalfonden shortet 1,20 pct.Arrow Street øge..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas-konkurrent: Møllepriser er faldet 13 pct. på årsbasis
2
Aktier/tendens: Topdanmark kan få hovedrolle i neutralt marked
3
OK18: Overraskede lønmodtagere venter på svar fra staten
4
Pandora/Carnegie: Løfter kursmålet til 700 kr.
5
Milliardsalg af L'easy vakler - citat

Relaterede aktiekurser

Zealand Pharma A/S 93,30 -0,2% Fald i aktiekurs

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2018  Disclaimer Cookie- og privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. april 2018 20:52:31
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180423.5 - EUROWEB2 - 2018-04-23 20:52:31 - 2018-04-23 20:52:31 - 1 - Website: OKAY